Genetix Pharmaceuticals, a leader in gene therapy of somatic stem cells, announced today the company’s clinical program to treat Adrenoleukodystrophy (ALD). The company is developing a gene therapy product in collaboration with Professor Patrick Aubourg and Doctor Nathalie Cartier of the National Institute of Health and Medical Research (INSERM). Genetix is planning to file an IND to expand the development in the US, as well as to expand the ongoing trial in France. The current development timeline should make the product commercially available to patients by 2014. Patrick Aubourg and Nathalie Cartier will become scientific advisors to Genetix’s ALD clinical programs.
ALD is a devastating disease that afflicts 1/17,000 males with onset of severe cognitive and neurologic deficits between the ages of 5 and 12, or in adulthood. It progresses to death within 3-10 years of diagnosis. Many people became familiar with ALD from the 1992 movie Lorenzo's Oil, which featured a young boy affected with this disease.
ALD is currently treated with allogeneic bone marrow transplantation when there is an appropriate donor. Even so, the graft sometimes does not take and there is Graft Versus Host Disease leading to death in 15% of children and at least 30% of adults post transplant. For those patients who survive the transplant procedure, the disease is stabilized and no longer progresses. In 50% of the patients who survive, Graft Versus Host Disease or delayed hematological reconstitution delay the time at which disease is stabilized, allowing the disease to have progressed further before stabilization.
Patrick Aubourg, M.D. of Inserm-University Paris Descartes commented, “We are delighted to develop this ground breaking gene therapy product together with Genetix, the leading gene therapy company. Our future close scientific collaboration is off to a good start. Production of large GMP batches is underway, which will allow us to rapidly treat the rest of the patients in this clinical trial. We look forward to working with Genetix to expand the trials and acquire the pivotal data and regulatory approvals needed to bring this product to market.”
Gene therapy places a healthy gene into the patients’ own bone marrow stem cells. In the first two patients described in the November issue of Science, the disease has been stabilized. To view the Science article, click on the following link: http://www.sciencemag.org/cgi/content/abstract/326/5954/818
Genetix’s gene therapy approach has the following advantages over allogeneic bone marrow transplantation: